Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Company details
Decision Resources Inc.
The worldwide leader in market research publications, advisory services and consulting
The company in detail
Profile
Each year, more than 1,000 of the world's leading organizations and 50 of the largest global pharmaceutical companies turn to Decision Resources for their strategic planning, market development, technology management, and competitive intelligence requirements. Decision Resources' strategic information services link clients with a global network of industry specialists expert at assessing both the promise of technology and the realities of markets and competition.
Decision Resources, Inc., provides a range of products and services to executives in the pharmaceutical and biotechnology industries. Our offerings include primary and secondary research publications, multiclient advisory services, and customized consulting.
Decision Resources enjoys a worldwide reputation for providing outstanding value to clients; enduring relationships are the hallmark of our success. We differentiate ourselves from competitors in several important ways:
- Early identification and analysis of the implications of global industry trends.
- Professional quality and experience of our worldwide staff and network of experts.
- Exceptional client service and response to client needs.
Services
Press Releases
(3rd Sep 2008) Company’s Growth Attributed to Nurturing Brand Companies More
(28th Aug 2008) Competition from Chinese makers present considerable challenge to branded western drug companies seeking to penetrate market, according to a new report from decision resources More
(28th Aug 2008) Utah and Mississippi rank very low in treatment rate for Asthma and Chronic Obstructive Pulmonary Disease, according to a new analytics tool from Decision Resources More
(26th Aug 2008) Most surveyed MCO pharmacy directors do not place cost control measures on branded antiretroviral drugs, according to a new report from Decision Resources More
(21st Aug 2008) Personalized medicine has the potential for good and bad, More
(18th Aug 2008) Physician treatment patterns and drivers will vary based on drug’s safety, efficacy and cost. - Decision Resources expands Emerging Markets report series to include India More
(14th Aug 2008) Massachusetts, Maine and Vermont have the highest percentages of dyslipidemia patients who have prescription drug coverage but are currently untreated, according to a new analytics tool from Decision Resources More
(13th Aug 2008) Expected approvals of biologic agents will expand treatment options for patients who fail conventional drug treatment, according to a new report from Decision Resources More
(12th Aug 2008) Owing to well-established and effective insulin-based therapies, market growth will be modest through 2017, according to a new report from Decision Resources More
(11th Aug 2008) Lamictal is the leading single-agent in first-, second- and third-line therapy, according to a new report from Decision Resources More
(11th Aug 2008) Decision Resources introduces the only healthcare analytics tool that assesses the number of insured patients who have a specific disease, but are untreated More
(6th Aug 2008) However, pharmacy directors disagree about formulary inclusion for key emerging biologic agents that will launch for the disease in the next few years, according to a new report from Decision Resources More
(5th Aug 2008) Total drug market for pain will reach more than US$47 billion in 2023, according to a new report from Decision Resources More
(29th Jul 2008) Crestor will remain the clinical gold standard drug through 2016, according to a new report from Decision Resources More
(24th Jul 2008) Formerly of Harvard University’s office of General Counsel, attorney will be responsible for all legal aspects of the company More
(22nd Jul 2008) Gleevec will achieve clinical gold standard status by 2011, according to a new report from Decision Resources More
(17th Jul 2008) Few first-line patients receive dopamine agonists despite these agents’ ability to stave off Levodopa treatment, according to a new report from Decision Resources More
(15th Jul 2008) Up-to-Date Analysis of the Alzheimer’s Disease Market Now Available from Decision Resources More
(15th Jul 2008) Owing to safety, Escitalopram will remain as the clinical gold standard treatment, according to a new report from Decision Resources More
(14th Jul 2008) Prevalence of the disease will rise as improved treatments increase patient longevity, according to a new report from Decision Resources More
(10th Jul 2008) Other atypicals thrive by capturing specific patient populations, according to a new report from Decision Resources More
(9th Jul 2008) Most surveyed MCO pharmacy directors will move Razadyne and Razadyne ER from tier 2 to tier 3 when generic Razadyne is launched, according to a new report from Decision Resources More
(1st Jul 2008) Advantages in efficacy and safety will make Liraglutide the new Clinical Gold Standard drug by 2011, according to a new report from Decision Resources More
(26th Jun 2008) A drug with superior efficacy to Avastin at improving visual acuity when used with laser photocoagulation would earn a 20 percent patient share, according to a new report from Decision Resources More
(25th Jun 2008) Physician treatment patterns and drivers will vary by geographic location, according to a new report by Decision Resources More
(24th Jun 2008) Multikinase inhibitors, most notably Pfizer’s Sutent, will continue to dominate the market, according to a new report from Decision Resources More
(19th Jun 2008) Hepatitis C Virus market is one of the most active areas of infectious disease drug development in recent years, according to a new report from Decision Resources More
(18th Jun 2008) Physician education will be a critical step in the adoption of emerging Alzheimer’s Disease therapies, according to a new report from Decision Resources More
(18th Jun 2008) The presence of Comorbid Depression influences physicians to prescribe a Selective Serotonin Reuptake Inhibitor, according to a new report from Decision Resources More
(17th Jun 2008) Acquisition expands Decision Resources, Inc.’s portfolio to include global physician and consumer digital market research More
(17th Jun 2008) Modest market growth will be driven by the arrival of once-daily formulations of dopamine agonists, according to a new report from Decision Resources More
(16th Jun 2008) Among currently available therapies, Enbrel and Humira will continue to dominate the market through 2017, according to a new report from Decision Resources More
(12th Jun 2008) Advantages in efficacy and delivery will make Qnexa the new clinical Gold Standard drug by 2011, according to a new report from Decision Resources More
(11th Jun 2008) Ustekinumab will earn a 5.4 percent patient share by 2012, according to a new report from Decision Resources More
(10th Jun 2008) Market will be driven by increasing use of established agents that include Avastin, Erbitux, Rituxan/Mabthera, according to a new report from Decision Resources More
(9th Jun 2008) Sales of currently dominant acetylcholinesterase inhibitors will decrease by nearly half over the next decade, according to a new report from Decision Resources More
(3rd Jun 2008) Wyeth’s Pristiq to benefit from key change in physicians’ prescribing patterns, according to a new report from Decision Resources More
(3rd Jun 2008) However, annual market growth will increase to 4.5 percent from 2012 to 2017 due to emergence of premium-priced drugs, according to a new report from Decision Resources More
(2nd Jun 2008) New products from novel drug classes are addressing key unmet needs for highly treatment-experienced patients, according to a new report from Decision Resources More
(2nd Jun 2008) Decision Resources introduces the only healthcare analytics tool that assesses the number of insured patients who have a specific disease, but are untreated More
(29th May 2008) Overall market growth will be driven by launch of nine emerging therapies, including five oral agents, according to a new report from Decision Resources More
(28th May 2008) Prevalent COPD population will rise by nearly 19 percent as a result of increased diagnosis rates, according to a new report from Decision Resources More
(28th May 2008) New entries to China drug market to garner more than US$ 270 million in combined sales, according to a new report by Decision Resources More
(20th May 2008) Antibacterial drug development faces many challenges including heightened regulatory scrutiny and increasingly stringent reimbursement policies, according to a new report from Decision Resources More
(19th May 2008) However, launch of new agents will drive growth in the Long-Acting Beta-Agonist/Inhaled Corticosteroid class, according to a new report from Decision Resources More
(15th May 2008) Considerable opportunity remains for an Antiplatelet therapy that, combined with Aspirin, causes less bleeding than the combination of Plavix/Iscover and Aspirin, according to a new report from Decision Resources More
(13th May 2008) Results from the Enhance trial impacting physician prescribing patterns, according to a new report from Decision Resources More
(12th May 2008) High-priced emerging immunomodulators will drive robust market growth over the next decade, according to a new report from Decision Resources More
(8th May 2008) A drug used in combination with Velcade that could improve overall survival would earn a 45 percent patient share, according to a new report from Decision Resources More
(24th Apr 2008) However, Somaxon's Silenor will replace Ambien as the clinical gold standard for Insomnia in 2011, according to a new report from Decision Resources More
(23rd Apr 2008) Avastin used in combination with Taxol and Paraplatin will become the clinical gold standard treatment by 2011, according to a new report from Decision Resources More
(22nd Apr 2008) Nearly three-quarters of physicians have switched patients to Merck's Januvia, according to a new report from Decision Resources More
(22nd Apr 2008) Seroquel's successor, Seroquel XR, will earn a 16 percent patient share in the Bipolar Disorder market by 2016, according to a new report from Decision Resources More
(17th Apr 2008) Superior bacteriological eradication and activity against antibiotic-resistant pathogens earn Avelox gold standard status through 2016, according to a new report from Decision Resources More
(17th Apr 2008) However, up to 20 percent of surveyed MCO medicaid plans will remove branded Antipsychotics from formularies, according to a new report from Decision Resources More
(17th Apr 2008) Superior bacteriological eradication and activity against antibiotic-resistant pathogens earn Avelox gold standard status through 2016, according to a new report from Decision Resources More
(16th Apr 2008) Milnacipran seen as most promising emerging drug, according to a new report from Decision Resources More
(9th Apr 2008) Emerging agent GlaxoSmithKline's Rezonic demonstrating efficacy for delayed Chemotherapy-Induced Nausea and Vomiting, according to a new report from Decision Resources More
(8th Apr 2008) Surveyed physicians will use novel drugs from Schering-Plough and Vertex/Johnson & Johnson in 75 percent of non-responder patients, according to a new report from Decision Resources More
(7th Apr 2008) Less than 20 percent of patients diagnosed with the disease receive pharmacotherapy within a year of their diagnosis, according to a new report from Decision Resources More
(3rd Apr 2008) Jiangsu Simcere's Endostar and Merck Kgaa's Erbitux are the targeted therapies prescribed most often by Chinese physicians for the treatment of the disease, according to a new report by Decision Resources More
(3rd Apr 2008) Superior side-effect profile earns Vesicare gold standard status over sales-leading Detrol LA/Detrusitol XL, according to a new report from Decision Resources More
(2nd Apr 2008) Novartis's Exforge will remain the clinical gold standard through 2016, according to a new report from Decision Resources More
(2nd Apr 2008) Physicians indicate that most emerging therapies will not match the current gold standard, according to a new report from Decision Resources More
(1st Apr 2008) Growth will be driven by novel emerging therapies, including drugs from Arena and Amylin, according to a new report from Decision Resources More
(1st Apr 2008) Emerging drugs and label expansion of currently marketed agents will drive growth, according to a new report from Decision Resources More
(20th Mar 2008) Physicians indicate that most promising emerging therapies will not match the current gold-standard Avastin/Taxol/Paraplatin regimen's efficacy, according to a new report from Decision Resources More
(19th Mar 2008) Although two-thirds of surveyed physicians anticipate an increase in the number of patients treated for low HDL over the next two years, 19 percent of surveyed MCOs will not add novel HDL drugs to their formularies, according to a new report from Dec More
(19th Mar 2008) Statins will continue to dominate market despite patent expiries and increased use of fixed-dose combinations, according to a new report from Decision Resources More
(17th Mar 2008) acquiSition expands Decision Resources, Inc.'s offering to include the most accurate, comprehensive formulary solutions on the market today More
(13th Mar 2008) However, owing to safety and delivery end points, drugs from Eli Lilly and Boehringer Ingelheim will remain as the gold standard treatments, according to a new report from Decision Resources More
(11th Mar 2008) Lack of Flulike side-effects drives physician prescribing of Copaxone over an Interferon-Beta therapy, according to a new report from Decision Resources More
(10th Mar 2008) Following recovery from withdrawals of two cox-2 inhibitors, the Chronic Pain drug market will regain momentum, according to a new report from Decision Resources More
(6th Mar 2008) A drug's effect on cognitive decline is the most important attribute influencing prescribing decisions, according to a new report from Decision Resources More
(5th Mar 2008) The new Brands & Strategies: Atypical Antipsychotics report provides critical commercial analysis at the market, company, and brand level More
(4th Mar 2008) Nearly one-third of surveyed managed care organizations levy coinsurance charges and other protocols on Remicade and Humira, according to a new report from Decision Resources More
(3rd Mar 2008) Experts are cautiously optimistic about emerging vaccines, according to a new report from Decision Resources More
(27th Feb 2008) Although physicians report satisfaction with GlaxoSmithKline's Advair and Boehringer Ingelheim/Pfizer's Spiriva, significant need remains for a novel Anti-Inflammatory drug, according to a new report from Decision Resources More
(26th Feb 2008) Competitive advantages position GlaxoSmithKline's novel combination therapy to overtake Avodart as the clinical gold standard for the treatment of Benign Prostatic Hyperplasia by 2011 More
(25th Feb 2008) Entry of novel therapies including Rituxan/Mabthera and increased uptake of Cellcept will provide effective treatment options, according to a new report from Decision Resources More
(22nd Feb 2008) Following its approval, Erbitux will earn gold-standard status in 2011, according to a new report from Decision Resources More
(19th Feb 2008) Proposed changes focus on raising price premiums while cutting prices for existing drugs, according to a new Macroview update from Decision Resources More
(13th Feb 2008) Competitive advantages in efficacy will drive prescription rates, according to a new report from Decision Resources More
(11th Feb 2008) Seventy-nine percent of U.S. oncologists currently use Avastin to treat the disease, according to a new macroview update from Decision Resources More
(11th Feb 2008) Specialists consider decode genetics' dg-041 positioned to replace the leading Antiplatelet agent, according to a new report from Decision resources More
(5th Feb 2008) Following its launch in 2010, Myriad genetics' Flurizan will earn a 23% patient share in the United States, according to a new report from Decision Resources More
(4th Feb 2008) Physician familiarity and its better side-effect/safety profile are driving Aricept prescription rates, according to a new report from Decision Resources More
(30th Jan 2008) Surveyed neurologists identify a six-hour treatment window as area of greatest dissatisfaction, according to a new report from Decision Resources More
(28th Jan 2008) Advantages in drug delivery will drive prescription rates, according to a new report from Decision Resources More
(16th Jan 2008) AstraZeneca's Symbicort is gaining favor among physicians for use in the treatment of the diseases, according to new reports from Decision resources More
(16th Jan 2008) Current evidence on emerging therapies shows no significant improvements over existing drugs, according to a new report from Decision Resources More
(15th Jan 2008) Launches of new therapies will boost diagnosis and drug-treatment rates, according to a new report from Decision Resources More
(9th Jan 2008) Views on end points differ greatly for some indications, including Major Depression, according to a new report from Decision Resources More
(20th Dec 2007) Most physicians identify Genentech when asked what pharmaceutical company comes to mind when treating Colorectal Cancer, according to a new report from Decision Resources More
(19th Dec 2007) Acquisition expands Decision Resources, Inc.'s market research expertise in the antibiotic, antifungal and diagnostic imaging markets More
(18th Dec 2007) Merck/Kyorin's singulair has posted large gains in second-line patient share, and GlaxoSmithKline's Advair faces new competition from AstraZeneca's Symbicort, according to a new report from Decision Resources More
(17th Dec 2007) Seventy-five percent of newly diagnosed COPD patients do not receive drug therapy within the first year after diagnosis, according to a new report from Decision Resources More
(13th Dec 2007) Role and line of therapy of Novel Anti-MRSA Cephalosporins raise differing opinions from infectious disease and critical care specialists, according to a new report from Decision Resources More
(12th Dec 2007) Reimbursement restrictions will increase for Oncology products, according to a new report from Decision Resources More
(11th Dec 2007) Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's Golimumab and Abbott/Eisai's Humira to benefit from Cimzia's delayed entry to market, according to a new report from Decision Resources More
(10th Dec 2007) The new forthcoming Brands & Strategies: Non-Small-Cell Lung Cancer report from Decision Resources provides critical commercial analysis at the market, company, and brand level More
(6th Dec 2007) Growth will be driven by dominance of biologic TNF-Alpha inhibitors, according to a new report from Decision Resources More
(5th Dec 2007) Overall sales will remain static owing to generic erosion of currently available therapies, according to a new report from Decision Resources More
(4th Dec 2007) Acquisition will accelerate Decision Resources Inc.'s commercial expertise growth and add animal health research to its portfolio More
(4th Dec 2007) Opportunity remains for oral MRSA agents to treat Community-Acquired MRSA and reduce hospital stay and associated healthcare costs, according to a new report from Decision Resources More
(4th Dec 2007) Physicians rate Byetta as the most efficacious agent for weight loss on the market, and MCOs rate it the safest, according to a new report from Decision Resources More
(3rd Dec 2007) Key unmet needs will be addressed by novel treatment options that include Marshall Edwards' Phenoxodiol and Virexx's Ovarex, according to a new report from Decision Resources More
(27th Nov 2007) Only 60% of managed care organizations cover the Exelon patch, according to a new report from Decision Resources More
(26th Nov 2007) Five new agents for Multiple Myeloma will launch during the next decade, according to a new report from Decision Resources More
(19th Nov 2007) Vaccines from Wyeth and Glaxosmithkline will also be vying to capture shares of the escalating Pneumococcal vaccine market, according to a new report from Decision Resources More
(15th Nov 2007) Sanofi-Aventis will attempt to remain a leading player in the market, according to a new report from Decision Resources More
(15th Nov 2007) Abbott/Eisai's Humira is best positioned to draw market share in an increasingly competitive market, according to a new report from Decision Resources More
(14th Nov 2007) Market growth will be driven by launches of several therapies from 2011 to 2016, according to a new report from Decision Resources More
(14th Nov 2007) Amgen/Wyeth/Takeda's Enbrel will remain the most widely prescribed TNF-Alpha inhibitor, according to a new report from Decision Resources More
(14th Nov 2007) Need still exists for inexpensive, highly effective drug therapies for the China market, according to a new report by Decision Resources More
(12th Nov 2007) Growth will slow after 2011 owing to market saturation and Biogeneric erosion, according to a new report from Decision Resources More
(29th Oct 2007) Upheaval is forecasted for the markets of five chemotherapy side effect indications, according to a new report from Decision Resources More
(25th Oct 2007) Doctors disagree over which drugs are more effective, according to a new report from Decision Resources More
(24th Oct 2007) Biogeneric Herceptin may be the hidden gem for Biogeneric manufacturers seeking less crowded markets, according to a new report from Decision Resources More
(23rd Oct 2007) Many patients are under-treated, leaving considerable room for growth, according to a new report from Decision Resources More
(22nd Oct 2007) Amid escalating health care costs, payers are likely to limit access to premium priced agents in dermatology, according to a new report from Decision Resources More
(17th Oct 2007) Takeda will continue to dominate the Type 2 Diabetes market, according to a new report from Decision Resources More
(16th Oct 2007) Market potential for new oral agents is highest in prevention of stroke in patients with Atrial Fibrillation, according to a new report from Decision Resources More
(15th Oct 2007) Leadership position in the Osteoporosis market is driven by differentiation, according to a new report from Decision Resources More
(15th Oct 2007) Allergan's botox will be the most successful agent offering an alternative to Anticholinergics, according to a new report from Decision Resources More
(11th Oct 2007) Western brand small-molecule targeted agents compete with Chinese manufactured targeted biologics, according to a new report by Decision Resources More
(9th Oct 2007) Up to one quarter of managed care organizations fail to cover agents with proven benefit for cancer patients, according to a new report from Decision Resources More
(3rd Oct 2007) U.S. payers plan to place Biogenerics on lower tiers than originator brands, according to a new report from Decision Resources More
(2nd Oct 2007) Doctors disagree over which drugs are more effective, according to a new report from Decision Resources More
(2nd Oct 2007) AstraZeneca's Seroquel emerges as the Antipsychotic of choice in all lines of therapy, according to a new report from Decision Resources More
(1st Oct 2007) Sales of Merck's Januvia and Amylin/Eli Lilly/Alkermes's Byetta will help offset generic erosion, according to a new report from Decision Resources More
(26th Sep 2007) Huge opportunity exists for development of more effective therapies that can improve survival, according to a new report from Decision Resources More
(25th Sep 2007) Patent expiries of several leading agents will decrease overall market by US $400 million through 2016, according to a new report from Decision Resources More
(24th Sep 2007) Longer term growth of Diabetic Neuropathy market will be driven by launches of disease-modifying therapies, according to a new report from Decision Resources More
(18th Sep 2007) Chinese physicians confuse COPD with asthma, constraining market growth, according to a new report by Decision Resources More
(17th Sep 2007) Bristol Meyers Squibb/Otsuka Pharmaceutical's Abilify Leads Second-Line Therapy, According to a New Report from Decision Resources More
(12th Sep 2007) Long-term outlook more favorable as drugs from Eli Lilly and Glaxo Smith Kline will drive the market in 2016, according to a new report from Decision Resources More
(11th Sep 2007) Generic erosion of Zocor and Lipitor will cause market share of Statins to drop nearly 40% by 2016, according to a new report from Decision Resources More
(10th Sep 2007) Managed care organizations aggressively control access to biologics, according to a new report from Decision Resources More
Merck to surpass Pfizer as the leading company in the cholesterol-lowering agent drug market by 2011
(6th Sep 2007) Leadership position will be won through patent expiry, continued success of blockbusters, and launch of new drugs, according to a new report from Decision Resources More
(5th Sep 2007) Patient forecast projects significant expansion of drug-treated population, but only for a limited time due to a cohort effect, according to a new report from Decision Resources More
(5th Sep 2007) U.S. Biogeneric agents to reach $2 billion in sales by 2016, according to a new report from Decision Resources More
(4th Sep 2007) Sources cite China as having the highest mortality rate of asthma in the world, and Decision Resources finds low diagnosis rates and low drug-treatment rates as a possible rationale More
(30th Aug 2007) Physicians eager to add emerging agents into current regimens, according to a new report from Decision Resources More